In the bio-tech market, Quest Diagnostics (DGX) has been making some remarkable strides. The company has been engaging in a number of acquisitions such as LifeLabs, OhioHealth's Outreach Laboratory Services, Lab Assets from Allina Health, and PathAI Diagnostics, creating a platform for the acceleration of AI and Digital Pathology in cancer diagnosis, and extending its reach in North America and Canada. The firm also released impressive Q3 and Q2 2024 financial results and updated its full-year guidance, demonstrating strong revenue growth, thus steadily outperforming competitors on strong trading days. Several major organizations like Leerink Partners and StockNews.com have upgraded the DGX's rating to Strong-Buy and Buy respectively due to its resilient performance. Furthermore, the introduction of health coaching on questhealth.com and the introduction of a self-collection specimen for common genital tract infection testing at its nationwide facility demonstrate the company's commitment to innovative healthcare solutions. Lastly, Quest Diagnostics has been recognized as a \"Best Place to Work for Disability Inclusion\" for the seventh consecutive year, showcasing its dedication to inclusivity.
Quest Diagnostics DGX News Analytics from Tue, 02 Apr 2024 07:00:00 GMT to Wed, 08 Jan 2025 22:17:00 GMT - Rating 8 - Innovation 6 - Information 9 - Rumor -5
